The benefits of afatinib compared with chemotherapy, with regard to symptom control of cough and dyspnea, are observed regardless of common epidermal growth factor receptor (EGFR) (Del19 or L858R) mutation type. |
Improvements reported in lung cancer-related symptoms in patients with advanced non-small-cell lung cancer harboring the Del19 and L858R mutations add further support to use of afatinib as a first-choice treatment in these patient populations. |
1 Introduction
2 Methods
2.1 Study Population and Design
2.2 Patient-Reported Outcomes (PROs)
2.2.1 Assessment
2.2.2 Statistical Analysis
3 Results
3.1 Patient Population
Mean (SD) | Del19 | L858R | ||
---|---|---|---|---|
Afatinib | Chemotherapy | Afatinib | Chemotherapy | |
LUX-Lung 3 |
n = 110 |
n = 56 |
n = 90 |
n = 45 |
Cough | 36.7 (27.2) | 33.9 (23.6) | 32.6 (24.6) | 31.8 (27.8) |
Dyspnea | 22.1 (18.3) | 24.8 (23.8) | 21.9 (19.1) | 23 (23.7) |
Pain | 22.6 (23.0) | 23.5 (26.2) | 28.8 (24.6) | 23.1 (25.0) |
GHS/QoL | 66.4 (19.3) | 60 (23.4) | 66.0 (20.8) | 60.4 (20.2) |
Functional scales | ||||
Physical | 81.2 (19.0) | 77.4 (22.2) | 80.52 (19.13) | 77.27 (20.70) |
Role | 76.5 (27.0) | 72.6 (29.9) | 78.28 (26.52) | 73.11 (25.72) |
Emotional | 80.0 (16.8) | 73.2 (23.0) | 76.97 (18.08) | 72.54 (22.70) |
Cognitive | 87.6 (15.6) | 87.5 (17.5) | 84.83 (17.52) | 81.82 (19.95) |
Social | 79.8 (22.3) | 74.1 (25.2) | 78.84 (22.01) | 76.14 (27.23) |
LUX-Lung 6 |
n = 124 |
n = 59 |
n = 90 |
n = 43 |
---|---|---|---|---|
Cough | 36.6 (24.5) | 27.5 (23.7) | 37.9 (23.4) | 32.5 (28.4) |
Dyspnea | 24 (19.4) | 24.2 (19.0) | 25.6 (19.1) | 24.7 (22.8) |
Pain | 21.2 (20.0) | 24.6 (20.9) | 27.5 (23.1) | 21.1 (25.3) |
GHS/QoL | 64.5 (20.7) | 65.4 (15.9) | 60.1 (21.2) | 66.9 (22.6) |
Functional scales | ||||
Physical | 80.2 (20.1) | 80.5 (18.4) | 77.62 (15.8) | 80.5 (18.5) |
Role | 79.6 (25.4) | 79.2 (23.2) | 74.90 (23.1) | 82.5 (23.0) |
Emotional | 84.8 (16.3) | 80.7 (17.4) | 81.13 (18.2) | 79.7 (22.5) |
Cognitive | 89.3 (13.4) | 86.8 (15.7) | 83.14 (19.6) | 86.6 (16.3) |
Social | 74.4 (23.5) | 73.1 (21.8) | 73.18 (24.0) | 73.2 (25.0) |